[ET Net News Agency, 1 April 2021] Venus Medtech (Hangzhou) Inc. (02500) said its loss
attributable to owners of the parent was RMB181.99 million for the year ended 31 December
2020, compared to the loss of RMB380.72 million of the same period last year. Basic loss
per share was RMB0.45. No dividend will be distributed.
Revenue was RMB276.05 million, a year-on-year increase of 18.3%. (RC)